Table 3.

Arrhythmias elicited by a second exposure to PAF during perfusion with elevated K⁺ for norepinephrine (NA)

	PAF (nmol)
Perfusion solution modification	0	0.1	1	10	100
	VPB (%)
None	33	58	75	82	91
K elevated to 8 mM	0	0*	17*	0*	33*
K elevated to 15 mM K	17	17	17*	17*	17*
+0.1 μM NA	42	58	91	100	90
K elevated to 8 mM+0.1 μM NA	50	27	18*	45	18*
K elevated to 15 mM+0.1 μM NA	92*	92	92	92	100
	Bigeminy(%)
None	33	58	67	73	82
K elevated to 8 mM	0	0*	0*	0*	0*
K elevated to 15 mM K	17	17	17*	17*	17*
+0.1 μM NA	33	33	27	45	60
K elevated to 8 mM+0.1 μM NA	17	0*	0*	9*	0*
K elevated to 15 mM+0.1 μM NA	67	83	58	66	75
	Salvo(%)
None	33	25	42	45	55
K elevated to 8 mM	0	0	0	0*	17*
K elevated to 15 mM K	0	0	0	0*	0*
+0.1 μM NA	8	33	18	27	30
K elevated to 8 mM+0.1 μM NA	17	9	0	9	0*
K elevated to 15 mM+0.1 μM NA	58	75	66	58	83
	VT(%)
None	33	42	42	45	45
K elevated to 8 mM	0	0	0	0*	0*
K elevated to 15 mM K	0	0	0	0*	0*
+0.1 μM NA	25	8	18	27	20
K elevated to 8 mM+0.1 μM NA	17	9	0	0*	0*
K elevated to 15 mM+0.1 μM NA	58	58	33	33	58
	VF(%)
None	8	8	17	9	9
K elevated to 8 mM	0	0	0	0	0
K elevated to 15 mM K	0	0	0	0	0
+0.1 μM NA	8	8	9	18	0
K elevated to 8 mM+0.1 μM NA	8	0	0	0	0
K elevated to 15 mM+0.1 μM NA	0	8	0	0	0

Left coronary beds were initially exposed to PAF. The data represent group incidence (%) of arrhythmias during a second exposure to PAF (0–100 nmol). During this second exposure, PAF was delivered to the left coronary bed in combination with the perfusion solutions indicated. 0 nmol refers to PAF vehicle; n=12 per group. Throughout, the right coronary bed was perfused with unadulterated Krebs solution

^*P<0.05 versus none (no addition to Krebs perfusion).